NASDAQ: ZLAB · Life Sciences · 5 alerts · CIK 1704292
Share price
$23.47Close, Nov 16
Sector
Life Sciences
Industry
Pharmaceutical PreparationsSIC 2834
Today's reference numbers: shares from the company's latest SEC cover page, price from the latest market close. Not a valuation or a recommendation. All Zai Lab Ltd filings on SEC EDGAR ↗
Zai Lab Limited filed its Q3 2026 report as a large accelerated filer, reporting 1,124,448,350 ordinary shares outstanding as of October 31, 2026. The filing outlines significant risk factors related to its operations in mainland China, including regulatory uncertainties, manufacturing compliance, and geopolitical tensions.
Zai Lab reported third quarter 2026 total revenues of $108.2 million, representing a 2% sequential increase in net product revenue. The company highlighted positive clinical data for its internally developed ADC, zocilurtatug pelitecan (zoci), in small cell lung cancer and expects 2027 to be a pivotal year with its first potential U.S. BLA submission.
Term
Q3 2026
“We are approaching a defining period for Zai Lab, as we advance toward bringing our first internally developed innovative medicines to patients globally. The strong first-line combination data for zocilurtatug pelitecan (zoci) presented at ESMO strengthen our confidence in its potential to become an ADC backbone of choice in small cell lung cancer.”
Dr. Samantha Du, Founder, Chairperson and Chief Executive Officer of Zai Lab
“This profile supports taking a standard chemotherapy-free regimen into a global Phase 3 study and gives us a strong foundation to build on with T-cell engager combinations. Our registrational programs in SCLC and neuroendocrine carcinomas are advancing toward readouts that could support our first U.S. BLA submission in 2027.”
Rafael G. Amado, M.D., President, Head of Global Research and Development at Zai Lab